TargetGene Biotechnologies
Genome Editing for Living Organisms
Company Overview
Snapshot
Founded in October 2012 by Yoel Shiboleth and Dan Weinthal, TargetGene Biotechnologies operates with 1–10 employees. The company has raised $9.2 million across two funding rounds from two investors. In December 2019, TargetGene's CEO discussed their TGEE platform as a potential successor to CRISPR in gene editing.
Business overview
TargetGene Biotechnologies is an innovative biotechnology company focused on developing efficient and highly specific DNA editing solutions for living organisms. Utilizing its patented and patent-pending TGEE (genome editing engine) platform, the company has developed RNA-guided gene targeting. TargetGene aims to apply its TGEE platform for human gene therapy, specifically targeting inherited diseases and cell-based immunotherapy within the Health Tech & Life Sciences sector.
Strategic signal
In December 2019, TargetGene's CEO, Yoel Shiboleth, highlighted the potential of their TGEE platform as a next-generation gene editing tool, positioning it as a possible successor to CRISPR. This signals the company's ambition to advance gene therapy with proprietary technology, indicating a focus on innovation and market disruption in the biotechnology landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is TargetGene Biotechnologies' core technology?
- TargetGene Biotechnologies' core technology is its patented and patent-pending TGEE (genome editing engine) platform, which enables efficient and highly specific RNA-guided gene targeting in living organisms.
- When was TargetGene Biotechnologies founded and by whom?
- TargetGene Biotechnologies was founded in October 2012 by Co-founder & CEO Yoel Shiboleth and Co-founder & COO Dan Weinthal.
- What is the primary application of TargetGene Biotechnologies' TGEE platform?
- TargetGene Biotechnologies aims to implement its TGEE platform for human gene therapy, focusing on inherited diseases and cell-based immunotherapy.
- What was a significant development for TargetGene Biotechnologies in December 2019?
- In December 2019, an interview with CEO Yoel Shiboleth highlighted TargetGene Biotechnologies' TGEE platform as a potential replacement for CRISPR in gene editing, signaling its advanced capabilities.
- What was TargetGene Biotechnologies' collaboration with Monsanto in June 2016?
- In June 2016, Monsanto inked gene editing technology licensing deals with TargetGene Biotechnologies and Nomad Bioscience, indicating a strategic partnership in the agricultural biotechnology sector.